Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Is Eager to Expand in Specialty Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva’s integration of Barr is ahead of schedule, enabling the generics firm to think about strengthening its branded franchises.

You may also be interested in...



With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations

While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.

With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations

While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.

Oral MS Therapies Move Closer, But Still Far From Approval And Adoption

The arrival of an oral therapy for multiple sclerosis moved closer on Sept. 30, but it will still be an uphill climb: first to get past regulators, and then to gain acceptance from a skeptical field of prescribers

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel